Interstitial lung disease following coronavirus disease 2019.
Curr Opin Pulm Med
; 28(5): 399-406, 2022 09 01.
Article
in English
| MEDLINE | ID: covidwho-2285289
ABSTRACT
PURPOSE OF REVIEW The aim of this review was to summarize the recent data concerning interstitial lung disease after COVID-19, a field where knowledge is evolving very quickly. RECENT FINDINGS:
It has been found that a proportion of patients displayed fibrotic-like pattern on chest computed tomography shortly after COVID-19 pneumonia. Those lesions can potentially represent precursors of fibrosis, although most of them will resolve until 1 year postinfection. There was a wide range of the prevalence of post-COVID-19 interstitial lung disease detected in the literature, which can be attributed to the heterogeneous definition of lung abnormalities and the discrepancy of study design. The severity of acute COVID-19 disease has been linked to increased risk of residual imaging and functional abnormalities, while reduced DLco was the most common functional abnormality in long-term survivors. Studies indicated that pathophysiology of post-COVID interstitial lung disease shares common mechanisms with idiopathic pulmonary fibrosis. Regarding therapeutic strategies of post-COVID-19 interstitial lung disease, the role of immunosuppressive and antifibrotic treatment is currently under investigation.SUMMARY:
We still need to learn about the natural history of COVID-19 disease, allowing for a better targeting of therapeutic interventions through a multidisciplinary approach.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Lung Diseases, Interstitial
/
Idiopathic Pulmonary Fibrosis
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Curr Opin Pulm Med
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS